FDA Approves First Twice-Yearly HIV Prevention Option
HCPLive is a clinical news and information portal, offering physicians specialty and disease-specific resources, conference coverage, and interviews.
HCPLive is a clinical news and information portal, offering physicians specialty and disease-specific resources, conference coverage, and interviews.
Drs. Richman and Wartman discuss the benefits of using predictive and diagnostic AI, while cautioning about the implicit risks of overreliance on early, imperfect technology.
This clinical episode of Skin of Color Savvy features a discussion on UV safety and photo protection in patients with skin of color.
Findings highlight the ongoing burden of generalized pustular psoriasis and suggest patients may benefit from targeted biologic therapies like the FDA-approved spesolimab.
Findings highlight the ongoing burden of generalized pustular psoriasis and suggest patients may benefit from targeted biologic therapies like the FDA-approved spesolimab.
Discover groundbreaking insights on the VISIONARY trial, IgA nephropathy treatment, and the future of kidney care with expert Vlado Perkovic, MBBS, PhD.
Richard Pratley, MD; Vivian Fonseca, MD, FRCP; Ralph DeFronzo, MD; Richard Auchus, MD, PhD; and Natalie Bellini, DNP, FNP, BC-ADM, CDCES, discuss how the groundbreaking…
Johnson & Johnson seeks FDA approval for lumateperone (CAPLYTA) to significantly reduce schizophrenia relapse risk. Company submits an sNDA.
This clinical episode of Skin of Color Savvy features a discussion on UV safety and photo protection in patients with skin of color.
Veeral Sheth, MD, is joined by the director of marketing of eSight to discuss the 5th generation eSight Go, a device to enhance central vision…
These ADHAND trial data highlight the results of tralokinumab in those with atopic dermatitis on the hands who are candidates for systemic therapy.